Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Post Quarterly Sales of $260.66 Million

Brokerages forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) will post $260.66 million in sales for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have made estimates for Alnylam Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $240.40 million and the highest estimate coming in at $273.30 million. Alnylam Pharmaceuticals […]

Related Keywords

,Stevenm Paul ,Capital International Sarl ,Securities Exchange Commission ,Zacks Investment Research ,Manufacturers Life Insurance Company ,Alnylam Pharmaceuticals Inc ,Nasdaq ,Alnylam Pharmaceutical ,Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals Company Profile Get Rating ,Neuberger Berman Group ,Toroso Investments ,Get Rating ,Chardan Capital ,Director Steven ,Exchange Commission ,Berman Group ,World Investors ,Pharmaceuticals Company Profile ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Ratings ,Consensus ,